Ascendis Pharma's Price Target Increased After Positive Trial Results
Recently, a Jefferies analyst raised Ascendis Pharma's (NASDAQ: ASND) price target to $179 from the previous $174 while reaffirming a strong "Buy" rating. This change follows the release of encouraging clinical trial data for Navepegritide, Ascendis Pharma's innovative treatment aimed at helping children with achondroplasia.
New Insights in Pediatric Growth Treatment
Ascendis Pharma has recently disclosed significant trial results that underscore Navepegritide's effectiveness. The trial involved pediatric patients aged 2 to 11 years and demonstrated an impressive annual growth velocity (AGV) of 5.89 centimeters, well above the 4.41 centimeters recorded in the placebo group. This finding, marked by a p-value of less than 0.0001 at the 52-week point, indicates strong statistical significance.
Outcome Comparisons and Key Advantages
The results from Navepegritide's trials were notably similar to the Phase 3 outcomes of BioMarin's Voxzogo, which registered an AGV of 5.61 centimeters for their treatment compared to 3.94 centimeters for the placebo. Importantly, Navepegritide's once-weekly dosing schedule stands out as a clear advantage in treating achondroplasia, differentiating it from other options in the market.
Looking Ahead: Regulatory Submission Plans
As for the future, Ascendis Pharma plans to file a New Drug Application (NDA) for Navepegritide in the first quarter of 2025. This upcoming submission is expected to be one of the factors contributing to the optimistic outlook from analysts and the adjusted price target for the company's shares.
Positive Findings from the ApproaCH Trial
In additional news, Ascendis Pharma reported successful results from its Phase 3 ApproaCH trial, which evaluated TransCon CNP in children with achondroplasia. The trial highlighted a notable increase in annualized growth velocity over the placebo, further affirming the effectiveness of their therapeutic approach.
Investment Firms Show Support
A variety of investment firms, including Barclays, Goldman Sachs, BofA Securities, and Stifel, have voiced their support for Ascendis Pharma by keeping their "Buy" ratings intact, with price targets ranging from $175 to $200. Such endorsements strengthen Ascendis Pharma's position as the company looks to obtain regulatory approval for TransCon CNP in both the U.S. and Europe in 2025.
Updates on Funding and Financial Status
Moreover, Ascendis Pharma has announced significant developments, including a $150 million funding agreement with Royalty Pharma. They also secured U.S. approval for YORVIPATH, targeting adults with hypoparathyroidism. The company ended the quarter with a solid cash position of EUR259 million and is projecting revenues between EUR220 million and EUR240 million for SKYTROFA for the whole of 2024.
Frequently Asked Questions
What is the new price target for Ascendis Pharma's stock?
The new price target for Ascendis Pharma's stock is $179, up from the previous $174 as set by Jefferies.
What is Navepegritide and who is it intended for?
Navepegritide is a product candidate aimed at treating achondroplasia in children aged between 2 and 11 years.
What were the key findings from the latest trial of Navepegritide?
The latest trial revealed an impressive AGV of 5.89 centimeters per year, which is considerably better than the rate observed in the placebo group.
What other treatments is Ascendis Pharma working on?
Ascendis Pharma is developing additional treatments, including TransCon CNP for achondroplasia and YORVIPATH for adult hypoparathyroidism.
What is the revenue forecast for SKYTROFA in 2024?
The projected revenue for SKYTROFA in 2024 is expected to be between EUR220 million and EUR240 million.
